Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05937919 | 68Ga-PMD22 PET/CT Examination Targeting CLDN18.2 | unknown | Early Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT05715606 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 5, 2023 | clinicaltrials |
| NCT04610528 | A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression(TOT-HER3) | unknown | Early Phase 1 | 80 | SOLTI Breast Cancer Research GroupOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05891028 | 64Cu/68Ga Labelled EB-ss-CPT PET/CT Scan in Colorectal Cancer | unknown | Early Phase 1 | 10 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05875753 | 68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer | unknown | Early Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05851456 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT05830240 | A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer | unknown | Early Phase 1 | 9 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05831930 | The Effect of Nitozumab in the Treatment of Head and Neck Squamous Cell Carcinoma | unknown | Early Phase 1 | 62 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05828238 | Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05815394 | 177Lu-labeled NY108 SPECT Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05812677 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05093920 | Role of DEB-TACE Versus c-TACE in Treatment of HCC | unknown | Early Phase 1 | 30 | Sohag UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05801783 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer | unknown | Early Phase 1 | 10 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05759741 | Alterations of Gut Microbiome, Function, and Its Intervention After Defunctioning Ileostomy | unknown | Early Phase 1 | 64 | Huashan HospitalOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05744440 | Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCT | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05490849 | 68Ga-HX01 PET in Healthy Volunteers and Malignant Tumors Patients | unknown | Early Phase 1 | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05739227 | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04839731 | Combination 5-FU / Calcipotriene Cream for SCCIS/SCC | unknown | Early Phase 1 | 30 | Carilion ClinicOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05583201 | NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors | unknown | Early Phase 1 | 18 | jianming xuOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03099564 | Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | unknown | Early Phase 1 | 30 | Ashwin SomasundaramOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05131698 | Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma | unknown | Early Phase 1 | 31 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05691855 | 89Zr-labeled NY009 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05691881 | 68Ga-labeled NY105 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05691894 | Tracer Targeting FAP PET Imaging in Patients | unknown | Early Phase 1 | 20 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05686720 | Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer | unknown | Early Phase 1 | 12 | First Affiliated Hospital of Shantou University Medical CollegeOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05680662 | The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism | unknown | Early Phase 1 | 200 | Ministry of Health, Saudi ArabiaOTHER_GOV | 0 | Jan 11, 2023 | clinicaltrials |
| NCT05654077 | EBV CAR-T Cells for Nasopharyngeal Carcinoma | unknown | Early Phase 1 | 24 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05655676 | 89Zr-labeled NY008 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05616468 | BGT007 Cell Treatment of Nasopharyngeal Carcinoma | unknown | Early Phase 1 | 23 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05652530 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | unknown | Early Phase 1 | 19 | Shenzhen Pregene Biopharma Co., Ltd.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05651191 | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL | unknown | Early Phase 1 | 9 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05638256 | 68Ga-labeled NY104 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05519384 | Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia | unknown | Early Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05622240 | 99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT05016778 | A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | unknown | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05003427 | 68Ga-FAPI-04 PET/CT for the Detection of Oral Carcinoma | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05589961 | Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme | unknown | Early Phase 1 | 10 | The Second Hospital of Hebei Medical UniversityOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05034783 | [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients | unknown | Early Phase 1 | 20 | Peking Union Medical College HospitalOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT04974281 | PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC | unknown | Early Phase 1 | 50 | Fudan UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05013372 | CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | unknown | Early Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT03692663 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05480501 | Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia | unknown | Early Phase 1 | 9 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05478343 | Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 28, 2022 | clinicaltrials |
| NCT04996602 | Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC | unknown | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT05444322 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 18 | He HuangOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05438797 | The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer | unknown | Early Phase 1 | 3 | Sizhen WangOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05430945 | A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 100 | Zhejiang UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05382377 | NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors | unknown | Early Phase 1 | 18 | jianming xuOTHER | 1 | May 19, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2023source: clinicaltrials